Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by CUR2004on Nov 18, 2011 10:08am
245 Views
Post# 19248320

New study to guide initial biopsy decisions

New study to guide initial biopsy decisions

Beyond the Abstract - Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions , by Alexandre de la Taille, MD., Et Al.

E-mailPrint

BERKELEY, CA (UroToday.com) - This prospective, open-label, multi-centre European study evaluated the clinical utility of the PROGENSATM PCA3 (Prostate CAncer gene 3) Assay in guiding initial prostate biopsy decisions in men with suspicion of prostate cancer (PCa). Briefly, the results show that the PCA3 Score improves the prediction of initial prostate biopsy outcomes in these men and may be suggestive of PCa aggressiveness.

https://www.urotoday.com/prostate-cancer-1014/beyond-the-abstract-clinical-evaluation-of-the-pca3-assay-in-guiding-initial-biopsy-decisions-by-alexandre-de-la-taille-md-et-al.html

Bullboard Posts